Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables (2023 - 2025)

Historic Receivables for BioLineRx (BLRX) over the last 3 years, with Q2 2025 value amounting to $281000.0.

  • BioLineRx's Receivables fell 9267.28% to $281000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $281000.0, marking a year-over-year decrease of 9267.28%. This contributed to the annual value of $4.0 million for FY2024, which is 23282.83% up from last year.
  • Per BioLineRx's latest filing, its Receivables stood at $281000.0 for Q2 2025, which was down 9267.28% from $1.9 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Receivables ranged from a high of $4.0 million in Q3 2024 and a low of $281000.0 during Q2 2025
  • Its 3-year average for Receivables is $2.6 million, with a median of $3.3 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first surged by 23282.83% in 2024, then crashed by 9267.28% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Receivables stood at $1.2 million in 2023, then soared by 232.83% to $4.0 million in 2024, then plummeted by 92.89% to $281000.0 in 2025.
  • Its last three reported values are $281000.0 in Q2 2025, $1.9 million for Q1 2025, and $4.0 million during Q4 2024.